786
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Timing of hormone therapy and its association with cardiovascular risk and metabolic parameters in 4-vinylcyclohexene diepoxide-induced primary ovarian insufficiency mouse model

, , , &
Article: 2247094 | Received 22 Jul 2022, Accepted 07 Aug 2023, Published online: 21 Aug 2023

References

  • Huhtaniemi I, Hovatta O, La Marca A, et al. Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol Metab. 2018;29(6):1–9. doi: 10.1016/j.tem.2018.03.010.
  • Clark RA, Mostoufi-Moab S, Yasui Y, et al. Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the childhood cancer survivor study (CCSS) and the St jude lifetime cohort (SJLIFE). Lancet Oncol. 2020;21(3):436–445. doi: 10.1016/S1470-2045(19)30818-6.
  • Golezar S, Ramezani Tehrani F, Khazaei S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22(4):403–411. doi: 10.1080/13697137.2019.1574738.
  • Upton CE, Daniels JP, Davies MC. Premature ovarian insufficiency: the need for evidence on the effectiveness of hormonal therapy. Climacteric. 2021;24(5):453–458. doi: 10.1080/13697137.2021.1902496.
  • ACOG. Committee Opinion No. 698: hormone therapy in primary ovarian insufficiency. Obstet Gynecol. 2017;129(5):e134–e41.
  • Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency†. Hum Reprod. 2016;31(5):926–937.
  • Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi: 10.3109/13697137.2015.1129166.
  • NAMS. The 2017 hormone therapy position statement of the North American menopause society. Menopause. 2017;24(7):728–753.
  • Lee SR, Cho MK, Cho YJ, et al. The 2020 menopausal hormone therapy guidelines. J Menopausal Med. 2020;26(2):69–98. doi: 10.6118/jmm.20000.
  • Almeida M, Laurent MR, Dubois V, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017;97(1):135–187. doi: 10.1152/physrev.00033.2015.
  • Dubey RK, Imthurn B, Barton M, et al. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005;66(2):295–306. doi: 10.1016/j.cardiores.2004.12.012.
  • Graziottin A, Leiblum SR. Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J Sex Med. 2005;2 Suppl 3(s3):133–145. doi: 10.1111/j.1743-6109.2005.00129.x.
  • Virdis A, Ghiadoni L, Pinto S, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation. 2000;101(19):2258–2263. doi: 10.1161/01.cir.101.19.2258.
  • Lee HJ, Park MJ, Joo BS, et al. Effects of coenzyme Q10 on ovarian surface epithelium-derived ovarian stem cells and ovarian function in a 4-vinylcyclohexene diepoxide-induced murine model of ovarian failure. Reprod Biol Endocrinol. 2021;19(1):59. doi: 10.1186/s12958-021-00736-x.
  • Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–1599. doi: 10.1016/j.fertnstert.2016.09.046.
  • Webber L, Anderson RA, Davies M, et al. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open. 2017;2017(2):1–11.
  • Cleemann L, Holm K, Kobbernagel H, et al. Dosage of estradiol, bone and body composition in turner syndrome: a 5-year randomized controlled clinical trial. Eur J Endocrinol. 2017;176(2):233–242. doi: 10.1530/EJE-16-0582.
  • Van Dorp W, Mulder RL, Kremer LCM, et al. Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCareSurFup consortium. J Clin Oncol. 2016;34(28):3440–3450. doi: 10.1200/JCO.2015.64.3288.
  • Koebele SV, Bimonte-Nelson HA. Modeling menopause: the utility of rodents in translational behavioral endocrinology research. Maturitas. 2016;87:5–17. doi: 10.1016/j.maturitas.2016.01.015.
  • Brinton RD. Minireview: translational animal models of human menopause: challenges and emerging opportunities. Endocrinology. 2012;153(8):3571–3578.
  • Cao LB, Leung CK, Law PW-N, et al. Systemic changes in a mouse model of VCD-induced premature ovarian failure. Life Sci. 2020;262:118543. doi: 10.1016/j.lfs.2020.118543.
  • Reis F, Pestana-Oliveira N, Leite CM, et al. Hormonal changes and increased anxiety-like behavior in a perimenopause-animal model induced by 4-vinylcyclohexene diepoxide (VCD) in female rats. Psychoneuroendocrinology. 2014;49:130–140. doi: 10.1016/j.psyneuen.2014.06.019.
  • Christensen A, Pike CJ. Age-dependent regulation of obesity and alzheimer-related outcomes by hormone therapy in female 3xTg-AD mice. PLoS One. 2017;12(6):e0178490. doi: 10.1371/journal.pone.0178490.
  • Ebenebe OV, Ashley Z, Erickson JR, et al. A timing effect of 17-β estradiol on atherosclerotic lesion development in female ApoE−/− mice. Int J Mol Sci. 2020;21(13):4710. doi: 10.3390/ijms21134710.
  • Pollow DP, JrRomero-Aleshire MJ, Sanchez JN, et al. ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause. Am J Physiol Regul Integr Comp Physiol. 2015;309(12):R1546–R1552. doi: 10.1152/ajpregu.00170.2015.
  • Yin W, Maguire SM, Pham B, et al. Testing the critical window hypothesis of timing and duration of estradiol treatment on hypothalamic gene networks in reproductively mature and aging female rats. Endocrinology. 2015;156(8):2918–2933. doi: 10.1210/en.2015-1032.
  • López-Grueso R, Gambini J, Abdelaziz KM, et al. Early, but not late onset estrogen replacement therapy prevents oxidative stress and metabolic alterations caused by ovariectomy. Antioxid Redox Signal. 2014;20(2):236–246. doi: 10.1089/ars.2012.5112.
  • Noh H, Lee H, Kim S, et al. The efficacy of body mass index and total body fat percent in diagnosis obesity according to menopausal status. J Menopausal Med. 2019;25(1):55–62. doi: 10.6118/jmm.2019.25.1.55.
  • Brooks HL, Pollow DP, Hoyer PB. The VCD mouse model of menopause and perimenopause for the study of sex differences in cardiovascular disease and the metabolic syndrome. Physiology (Bethesda). 2016;31(4):250–257. doi: 10.1152/physiol.00057.2014.
  • Meng Q, Li Y, Ji T, et al. Estrogen prevent atherosclerosis by attenuating endothelial cell pyroptosis via activation of estrogen receptor α-mediated autophagy. J Adv Res. 2021;28:149–164. doi: 10.1016/j.jare.2020.08.010.
  • Chadwick CC, Chippari S, Matelan E, et al. Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci U S A. 2005;102(7):2543–2548. doi: 10.1073/pnas.0405841102.
  • Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521–574. doi: 10.1210/er.2007-0001.
  • Nishikawa S, Yasoshima A, Doi K, et al. Involvement of sex, strain and age factors in high fat Diet-Induced obesity in C57BL/6J and BALB/cA mice. Exp Anim. 2007;56(4):263–272. doi: 10.1538/expanim.56.263.